Gene therapy is currently being considered as a promising treatment for musculoskeletal diseases with considerable emphasis placed on arthritis[@b1][@b2][@b3][@b4]. Intra-articular gene therapy would target tissue using a vector that can infect articular cartilage and the synovial lining of the joint which contain the cell types chondrocytes and synoviocytes, respectively[@b5][@b6]. Osteoarthritis is characterized in the joint by tissue wear particles originating from the cartilage surface and increased inflammatory factors in the joint fluid[@b7]. Gene therapy has focused on supplementation of anabolic factors including insulin-like growth factor-I, transforming growth factor beta, bone morphogenetic protein 2, and inhibition of pro-inflammatory molecules using interleukin 4, soluble tumor necrosis factor receptor, and interleukin-1 receptor antagonist protein which inhibits the pro-inflammatory interleukin-1[@b3][@b8][@b9][@b10][@b11][@b12]. Treatment with these biological molecules requires long term and steady state dosing and both of these requirements are difficult to impossible using recombinant protein treatments but well suited for the gene therapy approach[@b5][@b13]. Various viral vectors have been studied for gene therapy use in the joint including herpes simplex virus, HIV based lentiviral vectors, adenovirus and adeno-associated virus (AAV)[@b3][@b6][@b14][@b15]. Adeno-associated virus as a therapeutic vector currently shows the most promise as it can genetically modify a variety of cells including non-dividing cells with minimal pathologic effects. As a result the gene of interest is expressed long term, and tissue tropism is only limited by capsid serotype receptor accessibility[@b2][@b16]. The wide tissue tropism partly comes from the existence of different serotypes, at least 12 of which have been described with over 100 variants in different animal species[@b17][@b18][@b19][@b20].

One challenge facing AAV as a gene therapy vector is the prevalence of neutralizing antibodies found in the patient population (\>50% for AAV 2)[@b21][@b22][@b23][@b24]. The IgG antibodies from nonpathogenic AAV infections have been proven to induce a neutralizing effect on AAV *in vitro*[@b22]. These antibodies drastically decrease the transduction efficiency of the vector resulting in a treatment with limited to no success[@b25]. Due to the similarity between AAV capsid serotypes and the cross reactivity antibodies can have to the capsid, the most effective assay that determines transduction inhibition is a neutralization assay which directly tests whether the virus is not only bound by antibodies, but actually neutralized. These experiments have been performed in humans, but not in the horse to our knowledge[@b19][@b21].

Cells *in vitro* are different in several ways from those in explants. A cell monolayer typically results in certain cell types based on adherence and growth conditions. Further cell passaging can induce dedifferentiation and phenotypic changes as shown in chondrocytes[@b26]. Exposure to cell surface and cell doubling is significantly different for monolayer versus explants, all critical variables that may influence vector transduction[@b27]. Many prior studies have been done with monolayer cell cultures due to the simplicity and ability to better control for variation in experiments. Because of the potential differences that may exist between transduction in monolayer and transduction of cells *in situ*, our goal was to test whether cell monolayers are a good approximation for transduction of tissue explant cultures.

The objective of this study was to determine whether transduction efficiencies in the monolayer culture model are an accurate representation of transduction efficiencies in tissue explants, a model more closely related to *in vivo* transduction. We hypothesized that there may be differences in transduction efficiencies due to the increased amount of extracellular matrix in explant tissues. Further, to maximize transduction efficiency *in vivo* we sought to investigate whether neutralizing antibodies existed in the joint fluid or the serum of the horse. We hypothesized that neutralizing antibodies would most likely exist to some of the AAV serotypes that have efficient transduction in equine synoviocytes and chondrocytes.

Results
=======

Flow cytometry of vector transductions
--------------------------------------

Flow cytometry was performed on monolayer and tissue explant cultures to analyze the transduction efficiencies of AAV serotypes. The percentage of cells transduced and expressing GFP provided an indication of the proportion of the cells in the population that were permissive to an AAV transduction. In brief, cartilage explants, synovium explants, chondrocyte monolayers and synoviocyte monolayers were cultured and transduced with AAVs 1, 2, 2.5, 3, 4, 5 and 6 at a dose of 8,000 virus particles per cell (VPC). All AAVs were self-complimentary and encoded the gene for green fluorescent protein (GFP). This allowed for the flow cytometric determination of which AAV produced the highest percentage of cells expressing GFP, and consequently which AAV was the most efficient at transducing the cell type/culture of interest. The results divided AAV serotypes into three classes based on preference for transducing explants or monolayers more efficiently: class I or those that transduced explants more efficiently than monolayer, class II or those that showed no difference between explant and monolayer transduction, and class III or those that transduced monolayer more efficiently than explants. In cartilage derived cultures class I consisted of AAV 2 and 2.5; class II consisted of AAV 3 and 4; class III consisted of AAV 1, 5 and 6. In cultures derived from synovium, class I consisted of AAV 1, 2, 2.5 and 6. Class II consisted of AAV 3, 4 and 5, and there were no serotypes that could be categorized as class III ([Figure 1](#f1){ref-type="fig"}). Flow cytometry revealed AAV2 and 2.5 to be the most efficient serotypes at transducing all tissue and culture types ([Figure 2](#f2){ref-type="fig"}). Between the two, AAV 2 was consistently more efficient than 2.5, but this was not significant. AAV 3 was similar to 2 and 2.5 in all cultures except for synovial explants and AAV 5 in all but synovial and cartilage explants. AAV 1, 4 and 6 had varying amounts of statistical similarity to the other serotypes but consistently transduced cells the least efficiently of all serotypes. The difference in transduction efficiencies between cartilage explants and chondrocyte monolayers is not significant while averaging across all serotypes. This difference is significant however, when comparing synovial explants and synoviocyte monolayers.

In a qualitative analysis of all the cultures ([Figure 3](#f3){ref-type="fig"} being a specific example) AAV 2 consistently appeared to have the best overall transduction efficiency. AAV 2.5 did not appear as efficient as the quantitative analysis showed. And finally AAV 1 and 4 often appeared to not transduce cells at all, while AAV 3, 5 and 6 had mixed results but usually presented transductions that were somewhat less efficient than AAV 2.

Role of cell surface glycans
----------------------------

We next wished to compare the role of cell surface receptors with serotype specific transduction in explants versus monolayers. It was hypothesized that the differences in transduction efficiencies between explants and monolayers seen in [Figure 1](#f1){ref-type="fig"} could be attributed to varying concentrations of cell surface receptors for AAV. A previous report[@b28] indicated that lack of heparan sulfate led to only a moderate decrease in AAV 2 transduction of cells. While the previous report examined the role of heparan sulfate, we also sought to determine the relationship of sialic acid (the other primary receptor specific to AAV 1, 4, 5 and 6)[@b29][@b30]. An experiment was performed where the primary cell surface receptors for AAV were enzymatically cleaved and transduction efficiencies compared to those of untreated controls. These experiments were carried out in cell monolayer and joint tissue explants at 1000 VPC in the presence of heparinase or neuraminidase. Enzyme treatment to remove cell surface receptors for AAV 2 included heparinase I and III, AAV 2.5 included both heparinase I and III and neuraminidase III, and AAV 5 included neuraminidase III.

After enzyme treatment, there was no longer a statistical difference in transduction efficiencies between synovial explant and synoviocyte monolayer for AAV 2 and 2.5. The enzyme treatment also removed the statistical difference in transduction efficiencies between cartilage explant and chondrocyte monolayer for AAV 5 transduction. Of note, enzyme treatment did not remove the statistical difference in transduction efficiencies between cartilage explant and chondrocyte monolayer for AAV 2 and 2.5. It was interesting to note that AAV 2.5 is a rational design chimeric capsid containing 5 amino acids from AAV 1 spliced into the backbone of AAV 2 (ref. [@b31]). While this capsid still utilizes heparan sulfate as the primary receptor, the inclusion of the additional five amino acids plays a significant but still unknown role in enhancing vector transduction in muscle. AAV 2.5 was the first example of a chimeric AAV vector used in a clinical trial[@b31]. The ability to mimic or partially mimic successful *in vivo* transduction with joint tissue explants offers the unique opportunity to exploit capsid library evolution that may confer a syntropic capsid for the joint superior to any of the several analyzed in this study.

Impact of neutralizing antibodies from equine serum and synovial fluid on serotype transduction
-----------------------------------------------------------------------------------------------

We next sought to understand the role of neutralizing antibodies. An experiment was performed to determine the concentrations of serum and synovial fluid that would prove to neutralize AAV transduction. In brief, serial dilutions of serum or synovial fluid were created from 1:12 to 1:200 with incomplete F12 media as the diluent. The 1:12 dilution would have the greatest concentration of serum or synovial fluid and consequently neutralizing antibodies (if present). These concentrations were then pre-incubated with AAVGFP particles for one hour prior to synoviocyte cell transduction. If neutralizing antibodies were found in any treatment, this would have prevented the AAVGFP particles from efficiently transducing the cells, resulting in fewer cells expressing the GFP transgene as quantified by flow cytometry measurement compared to a control transduction. Specifically, any neutralizing serum or synovial fluid treatment was recorded only if it inhibited at least half of the transduction compared to the untreated, positive control. Additionally, as an increase in concentration implies a commensurate increase in neutralizing factors, only the lowest concentration dilution of serum or synovial fluid was recorded as this would identify the minimum absolute amount of neutralizing antibodies required to effect a 50% change in transduction. This would additionally differentiate between the strength of neutralization against specific serotypes. For example, if a neutralizing concentration of 1:25 was demonstrated, the stronger concentration (1:12) would also cause neutralization. And for example, if neutralization at 1:200 was found against AAV1 and 1:25 against AAV2, this would imply a higher concentration and/or greater specificity of antibodies to AAV1 than to AAV2. It was found that no synovial fluid samples had neutralizing effects on AAV transduction ([Table 1](#t1){ref-type="table"}). Serum samples were only neutralizing to AAV 5 at the two highest concentrations tested and only to AAV 2 and 2.5 in one horse. Horses A and D were neutralizing to AAV 5 at a 1:12 dilution while horses B and C were neutralizing at a 1:25 dilution. Horse A was neutralizing to AAV 2 and 2.5 at only a 1:12 dilution.

Discussion
==========

Using GFP transduction and neutralization assays we demonstrated differences between explant and monolayer transduction efficiencies in the joint tissues of the horse using a wide range of AAV serotypes. We observed three classes of AAV capsid transduction. The varying preference with which AAV serotypes transduce culture types was in agreement with findings by Mason et al.[@b32] The serotype most effective at transduction overall was AAV 2. AAV 2.5, 3, 5 and 6 also were effective in varying culture conditions. This is in agreement with work done in monolayer cultures by Goodrich et al. that showed AAV 2, 3, 5 and 6 (AAV 2.5 was not included in the study) to be the most efficient serotypes tested[@b33]. In this study we extended the above analyses to the well-documented explant tissue model, previously shown to better represent *in vivo* joint tissue and surface glycans[@b34][@b35][@b36]. AAV 6 was found to be efficient in chondrocyte monolayers as in the previous study but less efficient in cartilage explants. Of note, AAV 2 and 2.5 were more effective in explants while AAV 5 and 6 were more effective in chondrocyte monolayers than in cartilage explants. This would predict that AAV 2 and 2.5 would perform better *in vivo*, all other variables being held constant. In fact, a recent study analyzing AAV 2 and 2.5 demonstrated persistent (80+ days) of increased transgene expression (400 ng/ml) supporting our explant studies[@b37]. The ability to mimic or partially mimic *in vivo* success with joint tissue explants offers the unique opportunity to exploit capsid library evolution that may offer syntropic capsids that are superior to the collection analyzed in this study.

To address the differences between explants and monolayers, an experiment was performed to enzymatically remove the cell surface receptors for AAV and determine if this equalized the AAV transduction efficiencies between the two. AAV 2 enzyme treatment included heparinase I and III, AAV 2.5 included both heparinase I and III and neuraminidase III, and AAV 5 included neuraminidase III. AAV 2 uses the proteoglycan heparan sulfate as the major binding receptor, and human fibroblast growth factor receptor 1 (FGFR1), hepatocyte growth factor receptor (HGFR), and the integrin αvβ5 as co-receptors[@b38][@b39][@b40][@b41]. It has been previously shown that AAV 2 transduction is not mediated by chondroitin sulfate moieties[@b40]. Perlecan, however, has been theorized to be a binding site for AAV based upon immunohistochemistry and a BLASTN search of AAV Rep recognition sequences within the human genome[@b42][@b43]. AAV 5 uses the sialylated glycan α-2,3-N-linked sialic acid for the major binding receptor[@b44]. AAV 2.5 is a chimera composed of AAV 2 with 5 amino acid substitutions from AAV 1 (which uses α-2,3- and α-2,6-N-linked sialic acid as major receptors). The primary receptor is still heparan sulfate and the role of the five amino acid substitutions is unknown[@b20][@b30]. This experiment revealed that a difference in AAV 5 transduction efficiency between cartilage explant and chondrocyte monolayer could be attributed to varying amounts of sialylated glycan. The difference in AAV 2 and 2.5 transduction efficiencies between cartilage explant and chondrocyte monolayer cannot be attributed to differences in heparin sulfate, and heparan sulfate or sialylated glycan, respectively since removal of these receptors did not reduce transduction. Finally, the difference between synovial explant and synoviocyte monolayer transduction efficiencies for AAV 2 and 2.5 can be explained by differences in heparan sulfate, and heparan sulfate or sialylated glycan, respectively. For experiments where changes in transduction efficiency between explants and monolayers are not explained by differences in primary cell surface receptors, there are several AAV secondary cell surface receptors[@b20][@b30] that could be contributing to the variable efficiencies. The concentrations of enzymes used to remove cell surface glycans followed the procedures by Shen et al. and were nearly 1000 times those demonstrated to significantly reduce AAV transduction by Summerford et al.[@b40][@b45] In several cases, the results of the AAV transductions did not match the efficiencies from [Figure 4](#f4){ref-type="fig"}. This could be due to either using a lower titer of virus (which was necessary to observe the effects of the enzyme) of 1000 VPC (as opposed to 8000 VPC) or the fact that the cells were analyzed at ten days (as opposed to thirty). Although we expected a greater decrease in transduction in the positive control, this degree of drop in transduction has been reported in the past with this dose of viral particles per cell[@b28]. In contrast, Summerford and Samulski found an 80% decrease in rAAV transduction after heparinase treatment; however, this finding used a viral dose of 2 VPC. The significantly higher dose of AAV used in this study is hypothesized to have led to a smaller enzyme treatment mediated decrease in transduction due to increased binding by AAV to co-receptors HGFR, αVβ5, and FGFR1[@b38][@b39][@b41]. Lower viral doses result in greater drops, however below 1000 viral particles per cell in joint tissues results in very low transduction efficiencies[@b37]. Regardless, it is of interest to determine if library select capsids with joint tropism utilize sialic acid or heparan sulfate on combination therapy.

There were several horses that demonstrated various levels of AAV neutralization. All horses tested had no synovial fluid neutralization to any serotype of AAV but serum neutralization of varying degrees to AAV 5. Of note, bovine AAV shares capsid homology with AAV 5[@b46]. The dilutions of serum that proved neutralizing in our study (1:12 and 1:25) could both be considered non-neutralizing according to an arbitrary cutoff of 1:50 that was used in the study by Boissier et al., and the 1:12 dilution could be considered non-neutralizing by the cutoff of 1:20 used in the study by Halbert et al[@b21][@b24]. The cutoff established by Halbert et al indicated dilutions of less than 1:20 can exhibit non-specific neutralization of AAV transduction, meaning AAV is neutralized by factors other than antibodies specific for the virus serotype. Horse A also revealed serum neutralization to AAV 2 and 2.5 but only at the highest concentration and neither of these neutralizations would be considered neutralizing by the previous cutoffs. There is known immune cross reactivity between serotypes so this test cannot prove whether a specific neutralized AAV serotype was responsible for a primary infection, if the neutralizing capability of the serum is indeed due to pre-existing antibodies. However, the experiment reveals that, in a clinical setting, it is favorable to use AAV 2, 2.5, 3 or 6 for gene therapy transduction in the horse. Others could theoretically be used if neutralization is tested before the gene therapy treatment. As neutralization was only seen in the serum, it would be most accurate for testing to use serum rather than synovial fluid for neutralization assays. This trend is in contrast to the work of Cottard et al. which demonstrated a strong correlation between serum and synovial fluid inhibition in humans[@b22].

In conclusion, this study reveals that AAV transduction efficiency can differ between explants and monolayers. One of the contributing factors could be the increased amount of extracellular matrix found in the explant. This suggests that monolayer cultures could provide an adequate, relative model for testing transduction efficiency for AAV serotypes *in vivo*, but explants may offer a more accurate model. Additionally, we have shown there is a possibility of serum neutralization to AAV 5 in some horses. This should encourage clinicians to perform AAV 5 neutralization tests before administration of AAV gene therapy vectors to horses.

Methods
=======

Transduction efficiencies
-------------------------

Tissues were harvested post mortem from four horses, aged two to five years old, and euthanized for other reasons. Joints displayed no OA pathology. Synovium was aseptically excised from the inside of the fetlock joint capsule and cartilage from the patella. Similarly sized explants approximating 5 mm squares were cut from the larger pieces and kept in wells of 48 well plates with 500 μL Ham\'s F12 media (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA), 1× antibiotic antimycotic (HyClone, Logan, UT, USA), and 1N HEPES buffer (Invitrogen) changed every other day. The remaining synovium and cartilage pieces were diced and digested as previously described[@b47]. Cells were plated in appropriately sized tissue culture flasks at a density of 100,000/cm^2^ for synoviocytes and 200,000/cm^2^ for chondrocytes. Cells were grown for four days, then trypsinized and replated in 48 well plates at the aforementioned plating density. Two days following plating, cells and explants were transduced with scAAV-eGFP serotypes 1, 2, 2.5, 3, 4, 5 and 6 from the Gene Therapy Center Vector Core Facility (Chapel Hill, NC, USA). The vector scAAV-eGFP (pHpa-trs-SK) construct and cross packaging has been described previously[@b48][@b49]. Transduction was preceded by rinsing cells in PBS and then 250 μL Ham\'s F12 media was put into the wells. scAAV-eGFP was added to the wells at a concentration of 8000 virus particles per cell (VPC). The virus incubated with the cells for four hours at 37°C and 5% CO~2~ and was then aspirated and replaced by complete F12 media. The day of transduction was considered day zero. On days 4, 8, 12, 16, and 20, fluorescent microscopy pictures were taken of the cells and explants. The microscope used was an Olympus IX70 (Center Valley, PA, USA) with a filter cube with excitation at 495 nm and emission at 521 nm and at 100× magnification. Software used to capture images was QCapture by QImaging (Surrey, BC, Canada) and no post processing occurred. On day thirty, explants were individually digested and plated immediately into wells according to the prior digestion protocol. The explant cells adhered to the well for two days and then all wells were trypsinized. PBS with 0.2% FBS was added and the suspension analyzed by flow cytometry. Suspensions were run through a CyAn ADP Analyzer (Beckman Coulter, Brea, California, USA) and data analyzed with Summit 4.3 software (Dako, Carpinteria, CA, USA). The percent of cells transduced was the final data set analyzed. A mixed model ANOVA was used with horses being considered random variables. Statistics were considered significant with a p-value \< 0.05.

Enzymatic desialylation and AAV transduction
--------------------------------------------

Explants of cartilage and synovium and monolayers of chondrocytes and synoviocytes were isolated from a horse as described prior. Cultures were treated with heparinase I and III (Sigma-Aldrich \#H2519 and \#H8891, respectively) and/or neuraminidase III (Sigma-Aldrich \#N7885) as described[@b45]. Briefly, cultures were treated with 3 U/ml heparinase I, 1.5 U/ml heparinase III, and/or 50 mU/ml neuraminidase in incomplete Ham\'s F12 media for two hours at 37°C and 5% CO~2~. Cultures were rinsed and scAAV-eGFP of 1000 VPC was added in incomplete Ham\'s F12 media and incubated for four hours at 37°C and 5% CO~2~. The lower level of 1000 VPC was shown to produce a more noticeable difference between enzyme treated and control samples as similarly found previously[@b28]. Finally, the virus suspension was removed and complete Ham\'s F12 media was added. At seven days post transduction the explants were digested and plated as previously described. On day ten the cells were analyzed with flow cytometry as described above. A fixed effects ANOVA was used for statistical analysis and significance was established at a p-value \< 0.05.

AAV neutralizing antibodies
---------------------------

Synovial fluid and serum were collected post mortem from four horses euthanized for other reasons, and independent to the horses prior. 293 cells were plated and grown in Dulbecco\'s modified Eagle\'s medium (DMEM, Invitrogen) supplemented as described above in 48-well plates to act as an indicator of AAV neutralization. Two days after plating, synovial fluid and serum dilutions of 1:12, 1:25, 1:50, 1:100 and 1:200 were created from the four animals with incomplete DMEM media. To the dilutions were added 8000 VPC of scAAV-eGFP serotypes 2, 2.5, 3, 5 and 6. The virus and serum or synovial fluid dilutions were incubated at 37°C and 5% CO~2~ for one hour. Following this incubation the mixtures were used in a four hour transduction of 293 cells. Post transduction the mixtures were replaced with complete DMEM. Six days post transduction the cells were analyzed with flow cytometry as described above. Neutralization was defined as a concentration of synovial fluid or serum that inhibited a transduction by at least 50% compared to the positive control (AAV treatment with no synovial fluid or serum). Only the neutralizing dilution with the weakest concentration of synovial fluid or serum was indicated for each combination of treatment type and serotype. Statistical analysis was performed using a fixed effects ANOVA, and significance was established at a p-value \< 0.05.
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![Comparison of transduction efficiencies within the same tissue of origination but different culture types.\
The graphs show flow cytometry analysis of the percent of cells transduced. Columns indicate mean percent and bars indicate standard error of the mean. Asterisks denote a significant difference between the explant and monolayer data in the specific AAV serotype tested. P-values \< 0.05 are considered significant.](srep05861-f1){#f1}

![Ranking of AAV transduction efficiency as the percent of cells transduced in the cell and culture types tested.\
Columns indicate mean percent and bars indicate standard error of the mean. Significance between serotypes is shown with letters. P-values \< 0.05 are considered significant.](srep05861-f2){#f2}

![Fluorescence micrographs of the cell and culture types tested showing the presence or not of AAV transduction with the vectors tested.\
Pictures are from a single animal twelve days after transduction. From top row to bottom row: cartilage explants, chondrocyte monolayers, synovial explants, and synoviocyte monolayers.](srep05861-f3){#f3}

![Comparison of AAV transduction rates as percent of cells transduced in cultures treated with heparinases I and III (for AAV 2 and 2.5) and neuraminidase (for AAV 2.5 and 5).\
Positive controls are denoted with dark fill and enzyme groups with light fill. Asterisks denote a significant difference between the enzyme treated and control group of the specific cell, culture, and virus type tested. "\-\-\-\--" denotes a significant difference between enzymatically treated explant and monolayer cells of the same derived tissue within the specific serotype.](srep05861-f4){#f4}

###### Values for the minimum dilution of synovial fluid (SF) and serum ("SF/serum") at which neutralization of AAV was found. For example, if a neutralizing concentration of 1:25 was found, the stronger concentrations (1:12) would also cause neutralization. "-" indicates no statistically significant neutralization at any dilution. Neutralization is defined as the weakest concentration of synovial fluid or serum treatment giving a transduction statistically, significantly less than 50% of the positive control (AAV treatment with no synovial fluid or serum)

                  Virus Serotypes:                      
  -------------- ------------------ ------ ----- ------ -----
  **Horse A:**          -/12         -/12   -/-   -/12   -/-
  **Horse B:**          -/-          -/-    -/-   -/25   -/-
  **Horse C:**          -/-          -/-    -/-   -/25   -/-
  **Horse D:**          -/-          -/-    -/-   -/12   -/-
